Abstract
The objective of this study is to determine the efficacy of adding a prokinetic agent to proton pump inhibitors (PPI) for the treatment of laryngopharyngeal reflux (LPR) disease. A prospective, randomized open trial comparing lansoprazole plus itopride to lansoprazole single therapy was performed for 12 weeks. Sixty-four patients with a reflux finding score (RFS) >7 and a reflux symptom index (RSI) >13 were enrolled and received either lansoprazole 30 mg once daily with itopride 50 mg three times daily or lansoprazole 30 mg once daily for 12 weeks. RSI and RFS were completed at baseline, after 6 weeks, and after 12 weeks. During the treatment period, RSI and RFS were significantly improved compared with the pretreatment scores in both study groups. Reductions of total RSI and globus symptom were significantly higher in the lansoprazole plus itopride group compared to the lansoprazole group. In the RFS, however, there were no significant differences between the two groups. In conclusion, itopride in addition to PPI did not show any superior RFS improvement compared to PPI single therapy, but was helpful in speeding up relief of reflux symptoms in LPR patients. Thus, itopride may be considered as the secondary additive agent in the PPI treatment of LPR patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DeVault KR, Castell DO (1999) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 94:1434–1442
Koufman JA (1991) The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 101:1–78
Kamel PL, Hanson D, Kahrilas PJ (1994) Omeprazole for the treatment of posterior laryngitis. Am J Med 96:321–326
Altman KW, Stephens RM, Lyttle CS, Weiss KB (2005) Changing impact of gastroesophageal reflux in medical and otolaryngology practice. Laryngoscope 115:1145–1153
Fass R (2000) Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 18:20–26
Hammer HF (2009) Reflux-associated laryngitis and laryngopharyngeal reflux: a gastroenterologist’s point of view. Dig Dis 27:14–17
Belafsky PC, Postma GN, Koufman JA (2001) The validity and reliability of the reflux finding score (RFS). Laryngoscope 111:1313–1317
Belafsky PC, Postma GN, Koufman JA (2002) Validity and reliability of the reflux symptom index (RSI). J Voice 16:274–277
Koufman JA, Amin MR, Panetti M (2000) Prevalence of reflux in 113 consecutive patients with laryngeal and voice disorders. Otolaryngol Head Neck Surg 123:385–388
Koufman J, Sataloff RT, Toohill R (1996) Laryngopharyngeal reflux: consensus conference report. J Voice 10:215–216
Vaezi MF (2006) Reflux-induced laryngitis (laryngopharyngeal reflux). Curr Treat Options Gastroenterol 9:69–74
Scarpellini E, Vos R, Blondeau K, Boecxstaens V, Farré R, Gasbarrini A, Tack J (2011) The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther 33:99–105
Müller P, Göksu MA, Fuchs W, Schlüter F, Simon B (2000) Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers. Aliment Pharmacol Ther 14:1225–1229
Ruth M, Hamelin B, Röhss K, Lundell L (1998) The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 12:35–40
Arai K, Takeuchi Y, Watanabe H, Tsukurimichi A, Uchida N, Imawari M (2008) Prokinetics influence the pharmacokinetics of rabeprazole. Digestion 78:67–71
Kim YS, Kim TH, Choi CS et al (2005) Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 11:4210–4214
Mushiroda T, Douya R, Takahara E, Nagata O (2000) The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos 28:1231–1237
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chun, BJ., Lee, DS. The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease. Eur Arch Otorhinolaryngol 270, 1385–1390 (2013). https://doi.org/10.1007/s00405-012-2341-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-012-2341-8